Addressing a preliminary injunction in patent litigation related to the Biologics Price Competition and Innovation Act (BPCIA), the US Court ...
Hosted on MSN3h
ADMA Loses 8.9% in a Month: How Should You Play the Stock?ADMA Biologics’ ADMA shares have lost 8.9% in a month against the industry’s growth of 6.6%. The company has put up a ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., Appeal Nos. 2024-1965, -1966, -2082, -2083 (Fed. Cir. Jan. 29, 2025) ...
The Office of Cannabis Management paused social equity applications after legal challenges and is now ready to move forward.
Enveric Biosciences (ENVB) announces that its wholly-owned subsidiary, Akos Biosciences has entered into two licensing agreements with ...
3d
Enveric's Akos Biosciences licensed its cannabinoid-COX-2 conjugate technology to Restoration Biologics for joint disease ...
Many transgender, nonbinary, and intersex Americans now face uncertainty about the status of their passport applications.
A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...
United Therapeutics Corp. (UTHR), a public benefit corporation, announced Monday that the U.S. Food and Drug Administration (FDA) has ...
has accepted the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for patients with advanced melanoma. The FDA granted the BLA Priority Review with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback